When Stephanie Culler co-founded Persephone Biosciences in 2017, she had a vision of decoding the microbiome to harness its potential for diagnostics, therapeutics, and preventative care. The vision is simple, but the execution is far more complicated. The microbiome is highly individual and constantly changing, shaped by diet, environment, disease, and a multitude of other factors. Making sense of that complexity and turning it into reliable, scalable therapies requires advanced tools in biology, data science, and manufacturing.
This approach has the potential to change how we approach human health, leveraging the microbiome as a core component of precision medicine. That future could include tailored microbial cocktails designed to predict disease risk, boost drug response, and strengthen immune resilience, especially for cancer patients undergoing chemotherapy or immunotherapy.
Dr. Culler’s career began after graduating with a PhD in Chemical Engineering from Caltech, when she joined a biotech company called Genomatica. Genomatica develops sustainable industrial chemicals through fermentation using engineered microbes. This process can convert simple materials like sugar into high-value chemicals. She began to ask: if we could reprogram microbes to make nylon, why couldn’t we program them to make patients more resilient to cancer treatments?
But her shift into medicine was personal as well as technical. After losing both of her grandmothers to cancer asl a teenager, Culler became fixated on how treatments could be more precise, less toxic, and more effective. It wasn’t until her time at Genomatica, where she saw the power of engineered biology to solve big problems, that the pieces started to come together.
Culler’s experience at Genomatica provided her with a systems-level understanding of how to program and scale microbial life. This later became the foundation of Persephone’s approach: leveraging these microbes to create live biotherapeutics that interact predictably with the immune system.
Microbiome-Based Diagnostics
The microbiome is not a static organ. It is shaped by everything from diet and stress to genetics and medications, and it changes every day. This variability makes it difficult to predict how someone will respond to a therapy based on their microbial makeup, but that’s exactly what companies like Persephone are trying to do: turn it into a reliable diagnostic and therapeutic tool.
As of 2023, the microbiome diagnostics market was valued at $143 million, with projections reaching over $429 million by 2032. That number is even higher when therapeutics are included, with some estimates suggesting a combined market surpassing $1.2 billion by 2030. This growth is being driven by falling sequencing costs, improved data analytics, and mounting evidence that the microbiome is intricately linked to human health.
The field is crowded, and many companies pursuing microbiome-based therapeutics are receiving mixed results. Finch Therapeutics, for example, decided to halt its PRISM4 trial and lay off staff after struggling to demonstrate strong efficacy for treating C. difficile. Even Seres Therapeutics, which successfully launched VOWST™, the first FDA-approved microbiome drug for C. diff, faced years of delays before making it to market.
Where Persephone Bioscience diverges from its competitors is in its data-first, diagnostics-led approach. Rather than starting with a disease and searching for a one-size-fits-all cure, Persephone begins with the patient. Their flagship program, ARGONAUT, is building one of the largest and most diverse datasets ever assembled on the microbiome, immune system, and cancer response. Using artificial intelligence, the company creates what it calls “microbial avatars” that simulate how a patient’s unique microbiome might influence their response to chemotherapy or immunotherapy.
This emphasis on predictive diagnostics rather than therapeutic endpoints gives Persephone a strategic edge. While many competitors focus on more narrow targets like single-disease applications, Persephone sees the microbiome as a foundational layer of precision medicine. Their goal is not only to treat disease, but also to prime the body’s response before treatment begins.
Unlike other players in the field who use limited donor samples and small datasets, Persephone’s approach is based in inclusion. ARGONAUT is intentionally enrolling patients from a wide range of racial, ethnic, and geographic backgrounds in an effort to correct the bias baked into much of today’s biomedical research. By building a more representative baseline, Persephone hopes to deliver diagnostics and therapies that work for everyone.
Persephone’s Growth and Milestones
Over the past few years, Persephone Biosciences has evolved from a promising startup into a company with serious clinical traction and growing investor confidence. Their ARGONAUT study is where Persephone is focusing most of their clinical efforts. The study is being conducted in collaboration with partners like Kroger Health to extend trial access to patients through retail clinics and pharmacies to bring precision medicine into community settings.
Persephone’s other notable programs include:
- “Poop for the Cure” is a program aimed at accumulating as much multi-omics data as possible to support their current and upcoming initiatives. They’re asking healthy participants, cancer patients, and babies to send in stool samples to expand their working dataset.
- AMBROSIA, a food-as-medicine trial that focuses on patients at high risk of colorectal cancer. It explores how dietitian-led nutrition programs affect the microbiome and related biomarkers. As of early 2025, the program has reached full enrollment.
- ARTEMIS, a pediatric clinical trial that evaluates the effect of an infant synbiotic (which combines prebiotics and probiotics) that supports early immune development. They’ll be monitoring up to 200 infants and toddlers to see how this synbiotic affects microbial colonization and immune outcomes.
To support these initiatives, Persephone secured $15 million in a seed funding round in 2022 from partners like First Bight Ventures, Propel Bio Partners, Y Combinator, Fifty Years, and the American Cancer Society’s BrightEdge Fund. Their subsequent funding round in early 2025 raised an additional $6.3 million to fund ongoing development and clinical studies.
What’s Next for Persephone?
Persephone is entering its next phase of growth, expanding its clinical pipeline, seeking new partnerships, and preparing to launch a consumer-facing product. Their ARTEMIS program is expecting early data imminently, and they are planning to use the results to launch a commercial infant health product by the end of 2025.
Results from the AMBROSIA study are expected later this year, and the ARGONAUT project is continuing to expand access through retail pharmacies and clinics. Their strategic mission to democratize and decentralize clinical trials is making real headway in including populations that are often left out of clinical research. Persephone is also working with Ginkgo Bioworks to develop anaerobic engineering toolkits for Bacteroides species, aiming to exert control over microbial strain behavior to develop live biotherapeutics to strengthen the health of patients undergoing immunotherapy and chemotherapy.
Looking ahead, the company’s roadmap includes licensing its microbiome and multi-omic tools to pharmaceutical partners so they can be integrated into early-stage drug development. By bridging diagnostics, therapeutics, and consumer health, Persephone is preparing to turn decades of research into actionable, accessible solutions for patients. If their trajectory continues, they may herald a future where microbiome medicine becomes the foundation of treatment strategy and is accessible to patients from all walks of life.